For what it's worth, I recently contacted Resverlogix and asked if the meetings with the EMA and FDA had in fact taken place and if so would they characterize those meetings to which I received the reply "Our discussions have gone as expected". To me, I agree that DM has recently spoken very confidently about the prospects of obtaining ph 3 approval so if the discussions have "gone as expected" then I imagine they are still confident. No guarantees of course. When one considers the cost to the US healthcare system of diabetics with cardio/renal issues one might think the FDA might be looking favorably at anything which has the potential to relieve some of this enormous burden ($34 billion a year in dialysis costs alone should be motivation enough to look seriously at potential answers)

I think perhaps the Zenith meeting is for shareholders to approve Eastern's latest PP. Could be wrong though.